Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B-cell non-Hodgkin ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• GAMIFANT (emapalumab-lzsg)

Snippet

Sponsor: Marcela V. Maus, M.D.,Ph.D. | Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING